Abbott Q4 adj EPS $1.50 (+12% YoY); FY2025 revenue $44.3B; FY2026 adj EPS guide $5.55–$5.80

ABBOTT LABORATORIES

2025-FY EPS reported $3.72 revenue$44,328,000,000

Q4 GAAP EPS $1.01, adjusted EPS $1.50 (+12% YoY); revenue $11.46B (+4.4% reported, +3.8% ex-COVID).
FY2025 adjusted EPS $5.15 (+10% YoY); revenue $44.3B (+5.7% reported, +6.7% ex-COVID).
FY2026 guidance: organic sales growth 6.5%-7.5%; adjusted EPS $5.55-$5.80 (midpoint +10%).
Medical Devices sales +12.3% reported (+10.4% organic); CGM sales $2.0B up 15% reported.
Agreed to acquire Exact Sciences (cancer diagnostics); close expected Q2 2026. FDA OK for Volt PFA System.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.